孟鲁司特钠对轻度持续性支气管哮喘患者血清中MMP-9、TIMP-1水平的影响

发布时间：2018-03-09 03:02

本文选题：支气管哮喘　切入点：MMP-9　出处：《青海大学》2013年硕士论文　论文类型：学位论文

【摘要】：目的：本研究通过采用酶联免疫吸附（Enzyme-Linked ImmunosorbnentAssay，ELISA）实验方法测定治疗前后血清中MMP-9、TIMP-1水平的变化，观察白三烯受体拮抗剂（孟鲁司特钠）对轻度持续性支气管哮喘患者血清中MMP-9、TIMP-1水平的影响。方法：选取轻度持续性支气管哮喘患者61例，随机分成治疗组29例和对照组32例，，治疗组使用常规治疗+孟鲁司特钠10mg每日一次口服,疗程为7-14天，对照组使用常规治疗,疗程为7-14天，采用ELISA法测定两组治疗前后血清MMP-9、TIMP-1水平，并对其变化进行分析比较。结果：①治疗7-14天后，治疗组血清MMP-9明显低于对照组(p0.05)，分别为22.75±6.51ng/ml、28.93±7.59ng/ml；治疗组治疗前患者血清MMP-9水平为29.07±7.83ng/ml，明显高于治疗组治疗后(p0.05)。②治疗7-14天后，治疗组血清TIMP-1明显低于对照组(p0.05)，分别为10.74±4.14ng/ml、13.75±2.59ng/ml；治疗组治疗前患者血清TIMP-1水平为13.76±3.53ng/ml，明显高于治疗组治疗后(P0.05)。结论：孟鲁司特钠可明显降低轻度持续性支气管哮喘患者血清中MMP-9和TIMP-1的水平。MMP-9和TIMP-1的水平可作为轻度持续性支气管哮喘患者疗效判断的指标。孟鲁司特钠可能会通过下调支气管哮喘患者血清MMP-9和TIMP-1的水平，减少气道细胞外基质沉积。
[Abstract]:Objective: to determine the level of MMP-9 and TIMP-1 in serum before and after treatment by Enzyme-Linked Immunosorbent Assayia Elisa. To observe the effect of leukotriene receptor antagonist (montelukast sodium) on the level of MMP-9 and TIMP-1 in patients with mild persistent bronchial asthma. Methods: Sixty-one patients with mild persistent bronchial asthma were randomly divided into treatment group (n = 29) and control group (n = 32). The treatment group was treated with 10 mg montelukast sodium once a day for 7-14 days, and the control group was treated with routine therapy. The serum levels of MMP-9 and TIMP-1 were measured by ELISA before and after treatment for 7-14 days. Results after 7 to 14 days of treatment, the serum MMP-9 of the treatment group was significantly lower than that of the control group (22.75 卤6.51 ng / ml, 28.93 卤7.59 ng / ml, respectively), and the serum MMP-9 level of the treatment group was 29.07 卤7.83 ng / ml, which was significantly higher than that of the control group (P 0.05.2, 7-14 days after treatment). The serum TIMP-1 in the treatment group was significantly lower than that in the control group (10.74 卤4.14 ng / ml, 13.75 卤2.59 ng / ml, respectively), and the serum TIMP-1 level in the treatment group was 13.76 卤3.53 ng / ml, which was significantly higher than that in the treatment group after treatment (P 0.05). Conclusion: montelukast sodium can significantly reduce the levels of MMP-9 and TIMP-1 in patients with mild persistent bronchial asthma. MMP-9 and TIMP-1 levels can be used as an index to judge the curative effect of patients with mild persistent bronchial asthma. By down-regulating the levels of serum MMP-9 and TIMP-1 in patients with bronchial asthma, Reduce airway extracellular matrix deposition.
【学位授予单位】：青海大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：R562.25;R96

【参考文献】